China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Accounts Payables came in at $837108.0 in Q1 2026, down 61.08% YoY from $2.2 million in Q1 2025, and down 6.06% on a QoQ basis from $891083.0 in Q4 2025.
China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Accounts Payables data on file, last reported at $837108.0 in Q1 2026.
- Quarterly Accounts Payables fell 61.08% year-over-year to $837108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $837108.0 (down 61.08% YoY) and the FY2025 annual result came in at $891083.0, down 59.18% from the prior year.
- Accounts Payables eased to $837108.0 in Q1 2026, from $891083.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.4 million in Q4 2022 to a low of $141036.0 in Q2 2024.
- A 5-year average of $975176.1 and a median of $831298.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables slumped 88.54% — and 2025, when it jumped 490.2%.
- Tracing CPHI's Accounts Payables over 5 years: stood at $2.4 million in 2022, then slumped by 59.57% to $966420.0 in 2023, then soared by 125.88% to $2.2 million in 2024, then slumped by 59.18% to $891083.0 in 2025, then slipped by 6.06% to $837108.0 in 2026.
- The last three Accounts Payables figures came in at $837108.0 (Q1 2026), $891083.0 (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 356.00 Mn |
| 10 | China Pharma Holdings | 42.13 Mn | 41.82 Mn | 83,566.00 | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 837,108.00 |
| Dec 31, 2025 | 891,083.00 |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 530,729.00 |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 390,239.00 |
| Jun 30, 2024 | 141,036.00 |
| Mar 31, 2024 | 647,828.00 |
| Dec 31, 2023 | 966,420.00 |
| Sep 30, 2023 | 831,298.00 |
| Jun 30, 2023 | 414,084.00 |
| Mar 31, 2023 | 851,882.00 |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 361,192.00 |
| Jun 30, 2022 | 349,805.00 |
| Mar 31, 2022 | 338,414.00 |
| Dec 31, 2021 | 841,622.00 |
| Sep 30, 2021 | 1.73 Mn |
| Jun 30, 2021 | 3.05 Mn |